<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278290</url>
  </required_header>
  <id_info>
    <org_study_id>HNinosBuenosAires-Triptorelin</org_study_id>
    <nct_id>NCT01278290</nct_id>
  </id_info>
  <brief_title>Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls</brief_title>
  <official_title>Triptorelin Acetate Utilization for the Early Diagnosis of Central Precocious Puberty (CPP) in Girls.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Niños R. Gutierrez de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Niños R. Gutierrez de Buenos Aires</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the specificity, sensitivity and diagnostic efficiency&#xD;
      of the Triptorelin Test in the assessment of CPP compared to GnRH test as gold standard.&#xD;
&#xD;
      Hypothesis: Aqueous Triptorelin Acetate is so efficient as GnRH to CPP assessment.&#xD;
&#xD;
      Study population are girls with suspicious clinical features of precocious puberty&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GnRH stimulation is the gold standard to distinguish between isolated premature thelarche&#xD;
      (PT) and CPP. However, intravenous GnRH for testing is not fully available in all countries.&#xD;
      To evaluate the diagnostic accuracy of a novel Triptorelin-test in the assessment of CPP&#xD;
      compared to the GnRH test, a validation study was performed. Girls who presented thelarche&#xD;
      with accelerated growth and/or advanced bone age were included. All girls underwent the two&#xD;
      tests in a randomized order. CPP was ascertained according to LH response under GnRH (gold&#xD;
      standard test).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LH</measure>
    <time_frame>3 hs</time_frame>
    <description>Levels of LH are measured at T 0 (before) and T 3 h y T 24 h (after) Triptorelin stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estradiol</measure>
    <time_frame>24 hs</time_frame>
    <description>Levels of Estradiol are measured at T 0 (before) and T 3 h y T 24 h (after) Triptorelin stimulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FSH</measure>
    <time_frame>3 hs</time_frame>
    <description>Levels of FSH are measured at T 0 (before) and T 3 h y T 24 h (after) Triptorelin stimulation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Central Precocious Puberty</condition>
  <condition>Sexual Precocity</condition>
  <arm_group>
    <arm_group_label>Triptorelin test AND LHRH test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo two tests with a test interval of at least 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LHRH test AND Triptorelin test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo two test with a test interval of al least 15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Triptorelin acetate and Gonadorelin acetate</intervention_name>
    <description>Triptorelin acetate test, using aqueous 0.1 mg/m2 subcutaneous. Gonadorelin test using 100 ug intravenous.</description>
    <arm_group_label>Triptorelin test AND LHRH test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Gonadorelin acetate and Triptorelin acetate</intervention_name>
    <description>Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.</description>
    <arm_group_label>LHRH test AND Triptorelin test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  premature thelarche and/or&#xD;
&#xD;
          -  accelerated growth velocity (above 90 percentile)&#xD;
&#xD;
          -  advanced bone age at least 1.5 year in relation to chronological age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contact with sources of exogenous estrogens in the last four months previous to&#xD;
             evaluation,&#xD;
&#xD;
          -  suspicion of peripheral precocious puberty,&#xD;
&#xD;
          -  previous central nervous system illness or suspicion of organic central precocious&#xD;
             puberty.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria G Ropelato, PhD</last_name>
    <role>Study Director</role>
    <affiliation>División de Endocrinología, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Analía V Freire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>División de Endocrinología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Niños Ricardo Gutierrez, División de Endocrinología</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1425SEFD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Niños R. Gutierrez de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Analía Freire</investigator_full_name>
    <investigator_title>Pediatric Endocrinology, PhD</investigator_title>
  </responsible_party>
  <keyword>Triptorelin acetate</keyword>
  <keyword>precocious puberty</keyword>
  <keyword>premature thelarche</keyword>
  <keyword>GnRH analog</keyword>
  <keyword>Diagnostic validation study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

